aTyr Pharma shares are trading higher after Wells Fargo initiated coverage on the stock with an Overweight rating and announced a price target of $17.
Portfolio Pulse from Benzinga Newsdesk
aTyr Pharma shares rose after Wells Fargo initiated coverage with an Overweight rating and set a price target of $17.
October 04, 2024 | 4:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo's initiation of coverage on aTyr Pharma with an Overweight rating and a $17 price target has positively impacted the stock price.
The Overweight rating and $17 price target from a reputable institution like Wells Fargo is likely to increase investor confidence and demand for aTyr Pharma shares, leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100